Acelyrin, Inc. (SLRN)

Compare

2.1500

-0.0250

(-1.15%)

At close: 4:00:01 PM EDT

2.1300

-0.02

(-0.93%)

After hours: 5:25:47 PM EDT

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheet Boards unanimously recommend stockholders vote “FOR” the merger Transaction expected to be completed in second quarter of 2025 SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of pa

GlobeNewswire 6 days ago

SLRN
-1.15%
ALMS
Acelyrin, Inc. (SLRN): One of the Best Short-Term Stocks to Buy Right Now

We recently published a list of 10 Best Short-Term Stocks To Buy Right Now. In this article, we are going to take a look at where Acelyrin, Inc. (NASDAQ:SLRN) stands against other best short-term stocks with a buying opportunity for investors. Thrilling highs, daunting lows, and the energized chase after the next big opportunity – […]

Insider Monkey 23 days ago

SLRN
-1.15%
Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’

President Trump’s nominee to run the FDA secured the Senate HELP Committee’s backing. Elsewhere, Sutro cut jobs and a cell and gene therapy pilot appeared to survive.

BioPharma Dive 27 days ago

SLRN
-1.15%
STRO

PLRX
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan

LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, in response to Tang Capital Partners’ continued rapid accumulation of 8.8% of ACELYRIN’S outstanding common stock, its Board of Directors has approved the adoption of a limited-duration stockholder rights plan (“Rights Plan”). The ACELYRIN Board and management te

GlobeNewswire 28 days ago

SLRN
-1.15%
3 Promising Penny Stocks With Over $100M Market Cap

As the U.S. stock market faces a sell-off driven by concerns over tariffs and economic uncertainty, investors are increasingly looking for opportunities that can offer resilience and potential growth. Penny stocks, while often associated with risk due to their smaller size and less-established nature, still hold promise when they are backed by strong financials. In this article, we explore three penny stocks that exhibit solid balance sheets and the potential for long-term value creation...

Simply Wall St. 29 days ago

GOSS

SLRN
-1.15%
KNDI
Is Acelyrin, Inc. (SLRN) the Best Micro Cap Stock to Buy Now?

We recently compiled a list of the 10 Best Micro Cap Stocks to Buy Now. In this article, we are going to take a look at where Acelyrin, Inc. (NASDAQ:SLRN) stands against the other micro cap stocks. Just as we overlook loose change, micro-cap stocks are often ignored for larger, more dominant enterprises. Investors trying to […]

Insider Monkey last month

SLRN
-1.15%
Sector Update: Health Care Stocks Lower Tuesday Afternoon

Health care stocks declined Tuesday afternoon, with the NYSE Health Care Index down 0.6% and the Hea

PREMIUM
MT Newswires last month

UNH

SLRN
-1.15%
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheetSOUTH SAN FRANCISCO, Calif. and LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS) (“Alumis”) and ACELYRIN, INC. (Nasdaq: SLRN) (“ACELYRIN”) today reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage biopharma company in immune-mediated diseases. Martin Babler, President, Chief Executive Officer and Chairman of A

GlobeNewswire last month

ALMS

SLRN
-1.15%
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN) and Alumis Inc. (Nasdaq: ALMS) today reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage biopharma company in immune-mediated diseases. Martin Babler, President, Chief Executive Officer and Chairman of Alumis, said, “Alumis an

GlobeNewswire last month

ALMS

SLRN
-1.15%
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

All-Stock Transaction with Alumis Maximizes Long-Term Value for ACELYRIN Stockholders LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, after due consideration in consultation with its independent financial and legal advisors, its Board of Directors determined that the unsolicited indication of interest from Con

GlobeNewswire last month

ALMS

SLRN
-1.15%
Neumora bids farewell to R&D head; Biohaven’s ‘one step forward, one step back’ data

Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Atara is cutting half of its staff after shelving two cell therapy programs.

BioPharma Dive last month

NMRA
-5.17%
SLRN
-1.15%
PLRX
Ozempic, Wegovy shortage resolved; Pfizer CEO is PhRMA’s new chair

The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a competing bid for Acelyrin and Intra-Cellular sales rose.

BioPharma Dive last month

PFE

SLRN
-1.15%
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences

LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP is the controlling shareholder, to acquire all of the outstanding shares of ACELYRIN for $3.00 per share in cash, plus a contingent value right that repr

GlobeNewswire last month

SLRN
-1.15%
ALMS
3 US Penny Stocks With Market Caps Over $30M To Watch

As U.S. stock markets experience a downturn following disappointing jobs and consumer sentiment reports, investors are reassessing their portfolios amid broader economic uncertainties. In such times, exploring alternative investment opportunities like penny stocks can be intriguing for those looking to diversify beyond established market giants. Although the term "penny stocks" may seem outdated, these smaller or newer companies can still present unique growth potential when backed by strong...

Simply Wall St. last month

SLRN
-1.15%
ANGI
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Topline data from Phase 3 ONWARD trials for Alumis’ ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026 Evaluation underway of development plan for ACELYRIN’s lonigutamab to confirm differentiation in a capital efficient manner Pro forma cash position of approximately $737 million as of December 31, 2024, provides runway into 2027, beyond expected multiple cl

GlobeNewswire 2 months ago

ALMS

SLRN
-1.15%
ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease

Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate potential for efficacy in line with standard of care and a more favorable safety profile Conducted positive end of Phase 2 FDA meeting; Phase 3 program expected to be initiated in Q1 2025 Topline Phase 3 data expected in second half of 2026; cash runway expected through mid-2027 Conference call to review unmet need in TED, new Phase 2 data and Phase 3 program design to be held today, January

GlobeNewswire 3 months ago

SLRN
-1.15%
Acelyrin Leads The Charge With 2 Other US Penny Stocks

As the U.S. stock market rebounds from a five-session losing streak, led by a rally in major technology companies, investors are keenly observing opportunities across various sectors. Penny stocks, while often seen as relics of past trading eras, continue to offer intriguing prospects for growth and value discovery. These stocks typically represent smaller or newer companies that can deliver significant returns when supported by strong financials and sound fundamentals.

Simply Wall St. 3 months ago

SLRN
-1.15%
NIO

NIOIF
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab

LOS ANGELES, Jan. 02, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a virtual investor event on Monday, January 6, 2025 at 4:30 PM ET to provide updated Phase 2 data for subcutaneous lonigutamab further supporting its potential for a best-in-class efficacy and safety profile in Thyroid Eye Disease (TED). The event will also

GlobeNewswire 3 months ago

SLRN
-1.15%
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis

Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve statistical significance Company continues focus on development of subcutaneous lonigutamab in thyroid eye disease, with initiation of Phase 3 program on schedule for Q1 2025 $562.4 million in cash, cash equivalents, and short-term marketable securities on September 30, 2024 projected to provide runway to mid-2027, including completion of planned Phase 3 trials and BLA-enabling activities for lon

GlobeNewswire 3 months ago

SLRN
-1.15%
Promising US Penny Stocks To Consider In November 2024

As the U.S. stock market experiences a temporary setback with technology shares sliding, investors' attention is turning towards alternative investment opportunities such as penny stocks. Despite their name suggesting an outdated concept, penny stocks remain a significant area of interest due to their potential for growth and affordability. These smaller or newer companies, particularly those with robust financials, can offer unique opportunities for investors looking to uncover hidden value...

Simply Wall St. 4 months ago

SLRN
-1.15%
GPRO

WRAP

Performance Overview

Return	SLRN	S&P 500 (^GSPC)
YTD	-31.53%	-10.43%
1-Year	-62.28%	+2.08%
3-Year	-88.06%	+17.37%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

Acelyrin, Inc. (SLRN)

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Acelyrin, Inc. (SLRN): One of the Best Short-Term Stocks to Buy Right Now

Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’

ACELYRIN Adopts Limited-Duration Stockholder Rights Plan

3 Promising Penny Stocks With Over $100M Market Cap

Is Acelyrin, Inc. (SLRN) the Best Micro Cap Stock to Buy Now?

Sector Update: Health Care Stocks Lower Tuesday Afternoon

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

Neumora bids farewell to R&D head; Biohaven’s ‘one step forward, one step back’ data

Ozempic, Wegovy shortage resolved; Pfizer CEO is PhRMA’s new chair

ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences

3 US Penny Stocks With Market Caps Over $30M To Watch

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease

Acelyrin Leads The Charge With 2 Other US Penny Stocks

ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab

ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis

Promising US Penny Stocks To Consider In November 2024

Performance Overview